Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT Issuance of stock under employee stock plans

Issuance of stock under employee stock plans at other companies

Journey Medical Corporation logo
Journey Medical CorporationDERM

Other financials

Income statement

See full
Revenue$129.9M+59.3%
Gross profit$118.9M+60.7%
Operating income$16.4M+212%
Net income$15.0M+194%
EPS (diluted)$0.11+185%

Balance sheet

See full
Cash & equivalents$34.4M-52.9%
Total debt$114.1M+3.6%
Total equity$220.6M+58.7%
Total assets$488.5M+38.6%

Cash flow

See full
Operating cash flow$12.6M
CapEx$158.0K+103%
Free cash flow$12.5M

Valuation

See full
Market cap$3.26B+91.5%
Enterprise value$3.34B+92.0%
P/S+0.6×

Profitability

See full
Gross margin91.1%+2.0pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.5×-0.3×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-K, filed February 25, 2026.

Filed
Feb 25, 2026, 4:07 PM EST
Fiscal year
FY2025
Accession
0001787306-26-000018
Line itemYear Ended December 31, 2025Year Ended December 31, 2024Year Ended December 31, 2023
Proceeds from issuance of common stock, net of issuance costs161,682
Repayment of long-term debt(100,000)
Proceeds from issuance of common stock upon exercise of stock options4,5972,8071,247
Proceeds from issuance of common stock for ESPP2,3761,7131,175
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs95,765
Proceeds from issuance of shares under ATM, net of issuance costs3,136
Net cash provided by financing activities6,97366,202101,323
Effect of exchange rate changes on cash168(235)(50)

Item 16. tem 16.

FAQ

What is Arcutis Biotherapeutics, Inc.'s issuance of stock under employee stock plans?
Arcutis Biotherapeutics, Inc. (ARQT) reported issuance of stock under employee stock plans of $1.06M in Q4 2025.
How has Arcutis Biotherapeutics, Inc.'s issuance of stock under employee stock plans changed year-over-year?
Arcutis Biotherapeutics, Inc.'s issuance of stock under employee stock plans decreased by 0.7% year-over-year, from $1.06M to $1.06M.
What does issuance of stock under employee stock plans mean?
Issuance of stock under employee stock plans

Ask your AI about Arcutis Biotherapeutics, Inc.'s issuance of stock under employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude